AI Generated Image
Inhibrx claims first win for long-sought immunotherapy target
STAT • • business
Key Points:
- Inhibrx announced that its experimental immunotherapy targeting the OX40 protein showed positive responses in patients with head and neck cancer.
- The most significant results were observed in a small subset of patients with HPV-positive tumors, which may limit the broader applicability of the drug.
- OX40 has been a challenging target for cancer treatments, with major drugmakers like Pfizer, Genentech, GSK, and AstraZeneca failing to develop effective therapies over the past 15 years.
- Inhibrx CEO Mark Lappe expressed satisfaction with the progress, highlighting the difficulty of advancing treatments in this area due to previous failures.
